ATHENS, Greece, Aug. 27, 2025 (GLOBE NEWSWIRE) -- C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing seaborne transportation services, announced today that it will release its second quarter financial results for the period ended June 30, 2025 before the market opens in New York on September 2, 2025. On September 2, 2025 at 10:00 am ET, the company’s management will host a conference call to present the results and the company’s operations and outlook. Slides and audio webcast: There ...

NORTH CANTON, Ohio, Aug. 27, 2025 /PRNewswire/ -- Diebold Nixdorf (NYSE: DBD), a world leader in transforming the way people bank and shop, today announced Octavio Marquez, president and chief executive officer, and Tom Timko, executive vice president and chief financial officer, will participate in a fireside chat at the Goldman Sachs Communacopia and Technology Conference on Wednesday, Sept. 10, 2025 at 9:30 a.m. ET.Management's live fireside chat will be accessible via webcast on Diebold Nixdorf's Invest ...

Company Overview - Horizon Aircraft (NASDAQ: HOVR) is an advanced aerospace engineering company developing one of the world's first hybrid electric Vertical Take-Off and Landing (VTOL) aircraft, the Cavorite X7 eVTOL [5]. Upcoming Events - Horizon Aircraft management will participate in the Gabelli Aerospace & Defense Symposium on September 4, 2025, in New York City, including a fireside chat and 1x1 investor meetings [1]. - On the same day, management will also attend the Deutsche Bank Aviation Forum for 1x1 investor meetings [2]. - From September 8-10, 2025, management will participate in the H.C. Wainwright Global Investment Conference in New York City, focusing on 1x1 investor meetings [3]. - Horizon Aircraft will be present at the Rare Earth Mines, Magnets and Motors 2025 event on September 23-24 in Toronto, where management will participate in a panel discussion and showcase a large-scale prototype [4]. Product Development - The Cavorite X7 eVTOL is designed to fly most missions like a normal aircraft while offering industry-leading speed, range, and operational utility, with a focus on safety and performance [5].

Core Insights - The article highlights a landmark meeting co-sponsored by LIXTE Biotechnology Holdings, focusing on the activation of oncogenic signaling as a novel cancer treatment strategy [1][2] - LIXTE's lead compound, LB-100, was presented as a first-in-class PP2A inhibitor that activates oncogenic signaling, leading to cancer cell toxicity [2][4] Group 1: Conference Highlights - The conference introduced a paradigm shift in cancer therapy, advocating for the activation of oncogenic pathways rather than solely inhibiting them [3] - LB-100 exemplifies this approach by inhibiting PP2A, which removes a cellular "off switch," resulting in uncontrolled signaling that drives cancer cells to self-destruction [4] - Presentations at the conference reinforced the recognition of PP2A inhibition as a new therapeutic frontier, supporting LB-100's role as a platform therapy [5] Group 2: Company Positioning - By co-sponsoring the meeting, LIXTE positioned itself as a global thought leader in innovative cancer therapies, demonstrating its commitment to advancing cancer research [6] - LIXTE is focused on developing therapies targeting the PP2A pathway, with LB-100 showing strong preclinical results and early-stage clinical tolerability [7] - The company is currently advancing a proof-of-concept trial in Ovarian Clear Cell Carcinoma, indicating its active role in clinical development [7]

All outstanding Class A ordinary shares of Aspen to be redeemed for cash and delisted from NYSE; Aspen preference shares to remain outstanding Further diversifies Sompo's portfolio geographically in high-growth international markets Key Transaction Benefits Strengthens underwriting expertise and presence in core specialty insurance and reinsurance lines Provides access to significant fee-based income through leading capital markets platform Transaction expected to be immediately accretive to ROE post-closin ...

Core Insights - Donaldson (DCI) reported quarterly earnings of $1.03 per share, exceeding the Zacks Consensus Estimate of $1.02 per share, and up from $0.94 per share a year ago, representing an earnings surprise of +0.98% [1] - The company posted revenues of $980.7 million for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 2.82%, and an increase from $935.4 million year-over-year [2] - Donaldson has outperformed the S&P 500, gaining about 12.3% since the beginning of the year compared to the S&P 500's gain of 9.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.93 on revenues of $923.02 million, and for the current fiscal year, it is $3.90 on revenues of $3.78 billion [7] - The estimate revisions trend for Donaldson was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Pollution Control industry, to which Donaldson belongs, is currently ranked in the top 11% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

BRANFORD, Conn., Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the dosing of the first patient in its Phase 1/2 clinical trial of ATR04-484, a topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor ("EGFRi")-associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impa ...

Core Insights - Hafnia Limited (HAFN) reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, but down from $0.51 per share a year ago, indicating an earnings surprise of +7.14% [1] - The company posted revenues of $231.16 million for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.02%, and down from $417.36 million year-over-year [2] - Hafnia Limited has surpassed consensus EPS estimates in all four of the last quarters, while it has topped consensus revenue estimates two times in the same period [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $224.09 million, and for the current fiscal year, it is $0.69 on revenues of $958.34 million [7] - The trend of estimate revisions for Hafnia Limited was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Transportation - Shipping industry, to which Hafnia Limited belongs, is currently ranked in the bottom 21% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Cellectar Biosciences, Inc. announced the acceptance of an abstract for oral presentation at the AACR Special Conference on Pediatric Cancer, focusing on interim data from the CLOVER-2 Phase 1b study of iopofosine I 131 in pediatric high-grade glioma patients [1][2] Group 1: Presentation Details - The oral presentation titled "Precision Radiotherapy for Incurable Brain Tumors: Phase 1b Dose & Regimen Optimization Study of Iopofosine I 131 in Inoperable Relapsed or Refractory Pediatric High-Grade Glioma, Interim Data Assessment" is scheduled for September 26, 2025, at 2:50 pm Eastern time [3] - Jarrod Longcor, the chief operating officer of Cellectar, will present the findings during the plenary session [3] Group 2: Background on Pediatric High-Grade Gliomas - Pediatric high-grade gliomas are aggressive tumors affecting the brain and central nervous system, with poor median progression-free survival (PFS) of approximately 2.25 months and overall survival (OS) of about 5.6 months for relapsed cases [4] Group 3: CLOVER-2 Trial Overview - The ongoing Phase 1b trial of iopofosine I 131 includes children, adolescents, and young adults with relapsed or refractory pediatric high-grade gliomas across multiple sites in the U.S. and Canada [5] - The study evaluates the safety and tolerability of two dosing cohorts, with one cohort receiving 20 mCi/m² and the other 10 mCi/m², both separated by 14 days [5] - The trial aims to determine therapeutic activity defined by PFS and OS, as well as antitumor activity through tumor volume reduction [5] Group 4: Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on developing proprietary drugs for cancer treatment, utilizing its Phospholipid Drug Conjugate™ (PDC) delivery platform [6] - The company's product pipeline includes iopofosine I 131, CLR 121225, and CLR 121125, targeting various solid tumors with significant unmet needs [7][8] - Iopofosine I 131 has received multiple designations from the FDA, including six Orphan Drug and four Rare Pediatric Drug designations [9]